BRPI0411347A - combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia - Google Patents

combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia

Info

Publication number
BRPI0411347A
BRPI0411347A BRPI0411347-0A BRPI0411347A BRPI0411347A BR PI0411347 A BRPI0411347 A BR PI0411347A BR PI0411347 A BRPI0411347 A BR PI0411347A BR PI0411347 A BRPI0411347 A BR PI0411347A
Authority
BR
Brazil
Prior art keywords
treatment
vasopressin receptor
pde inhibitors
dysmenorrhea
receptor antagonists
Prior art date
Application number
BRPI0411347-0A
Other languages
English (en)
Inventor
Magda Nabil Bictash
Rachel Jane Russell
Pieter Hadewijn Van Der Graaf
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0313363A external-priority patent/GB0313363D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0411347A publication Critical patent/BRPI0411347A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçõES TERAPêUTICAS COMPREENDENDO INIBIDORES DE PDE E ANTAGONISTAS DOS RECEPTORES DE VASOPRESSINA PARA O TRATAMENTO DE DISMENORRéIA". A presente invenção refere-se a combinações sinérgicas de antagonistas da família dos receptores de vasopressina com inibidores de PDE.
BRPI0411347-0A 2003-06-10 2004-06-01 combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia BRPI0411347A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0313363A GB0313363D0 (en) 2003-06-10 2003-06-10 Therapeutic combinations
US48426603P 2003-06-30 2003-06-30
PCT/IB2004/001848 WO2004108138A1 (en) 2003-06-10 2004-06-01 Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea

Publications (1)

Publication Number Publication Date
BRPI0411347A true BRPI0411347A (pt) 2006-07-11

Family

ID=33512697

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411347-0A BRPI0411347A (pt) 2003-06-10 2004-06-01 combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia

Country Status (8)

Country Link
US (1) US20050049255A1 (pt)
JP (1) JP2006527257A (pt)
AR (1) AR044648A1 (pt)
BR (1) BRPI0411347A (pt)
CA (1) CA2528975A1 (pt)
MX (1) MXPA05013478A (pt)
TW (1) TW200503667A (pt)
WO (1) WO2004108138A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119088B2 (en) * 2003-02-19 2006-10-10 Pfizer Inc. Triazole compounds useful in therapy
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
US8796286B2 (en) * 2005-06-10 2014-08-05 Mezzion Pharma Co., Ltd. Agent for treatment of liver diseases containing pyrazolopyrimidinone derivative
BRPI0615972A2 (pt) 2005-07-29 2011-05-31 Concert Pharmaceuticals Inc composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto
TW200808805A (en) 2006-04-12 2008-02-16 Vertex Pharma Tetrahydropteridines useful as inhibitors of protein kinases
US20090221703A1 (en) * 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) * 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
MX377501B (es) * 2007-06-04 2025-03-10 Techfields Inc Profarmacos de nsaias con el piel y membranas con indices de penetracion muy altos y nuevos usos medicinales.
RU2630577C2 (ru) 2008-12-04 2017-09-11 Чунси ЮЙ Композиции интенсивного проникновения и их применение
SG179206A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
AU2010298190A1 (en) 2009-09-25 2012-05-03 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
CN111012914A (zh) 2012-01-18 2020-04-17 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
CN102766674A (zh) * 2012-07-25 2012-11-07 辉源生物科技（上海）有限公司 食蟹猴抗利尿激素受体v1a拮抗剂筛选平台的建立
US10350167B2 (en) * 2013-05-23 2019-07-16 The University Of Newcastle Targeted delivery of drugs to the myometrium via anti-oxytocin receptor antibodies
AP2017009744A0 (en) * 2014-08-06 2017-02-28 Pfizer Imidazopyridazine compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786486B3 (fr) * 1998-11-16 2000-12-08 Sanofi Sa Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6831074B2 (en) * 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
US6900200B2 (en) * 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7745630B2 (en) * 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators

Also Published As

Publication number Publication date
JP2006527257A (ja) 2006-11-30
AR044648A1 (es) 2005-09-21
US20050049255A1 (en) 2005-03-03
WO2004108138A1 (en) 2004-12-16
TW200503667A (en) 2005-02-01
CA2528975A1 (en) 2004-12-16
MXPA05013478A (es) 2006-03-09

Similar Documents

Publication Publication Date Title
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0411347A (pt) combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
ECSP055525A (es) Inhibidores de cinasas de tirosina
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
MX2008002293A (es) Uso novedoso de compuestos peptidicos para tratar dolor muscular.
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
DE60204553D1 (de) Jun kinase inhibitoren
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
BR0315167A (pt) Métodos para tratar a da dor administrando-se um antagonista do fator de crescimento de nervos e um analgésico opióide e composições contendo os mesmos
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BRPI0715698B8 (pt) produto, composição farmacêutica que o contém e uso de composto
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
UA88166C2 (ru) Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
UY28377A1 (es) Agentes terapeuticos
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]